ObjectiveTo systematically evaluate the association between Toll like receptor 2 (TLR2) gene I/D polymorphism and the risk of cancer.
MethodsWe searched PubMed, EMbase, The Cochrane Library (Issue 7, 2015), CBM, CNKI, VIP and WanFang Data to collect case-control studies about the association between TLR2 gene I/D polymorphism and the risk of cancer from inception to July 2015. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, meta-analysis was conducted using RevMan 5.3 software.
ResultsA total of 11 case-control studies involving 3 250 cancer patients and 4 332 controls were included. The results of meta-analysis showed that significant association was found between TLR2 gene I/D polymorphism and the risk of cancer (DD+DI vs. Ⅱ:OR=1.60, 95%CI 1.13 to 2.27, P=0.009; DD vs. Ⅱ+DI:OR=1.73, 95%CI 1.13 to 2.66, P=0.01; DD vs. Ⅱ:OR=1.99, 95%CI 1.22 to 3.24, P=0.006; DI vs. Ⅱ:OR=1.52, 95%CI 1.09 to 2.11, P=0.01; D vs. I:OR=1.54, 95%CI 1.14 to 2.09, P=0.005).
ConclusionTLR2 gene L/D polymorphism may be associated with cancer risk. Due to the limited quantity and quality of included studies, the conclusion should be verified in further studies.
